ZBH · 8-K · 20260805PR335108
Regulatory Approval Milestones
ZIMMER BIOMET HOLDINGS, INC. · 2026-08-05 · Importance 65 · Surprise 60 · In source text
The Monogram acquisition includes contingent value rights of up to approximately $570 million tied to product-development, regulatory and revenue milestones through 2030. Zimmer Biomet initially valued the related contingent consideration liability at $211.3 million, including $201.6 million allocated to the acquisition. The first development milestone was achieved in January 2026, while Monogram's fully autonomous robot remains in a clinical study. The company expects commercialization of the robotic technology to begin in 2027.
Key facts
- IPR&D recorded in the 2023 acquisitions: $36.3 million which upon receiving regulatory approval subsequent to the Embody acquisition date was reclassified to a definite-lived intangible and began amortizing. source
- The first development milestone for Monogram was achieved in January 2026. source
- IPR&D recorded in 2024 acquisitions: $7.0 million which upon regulatory approval was reclassified to a definite-lived intangible and began amortizing. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | — | IPR&D recorded in the 2023 acquisitions: $36.3 million which upon receiving regulatory approval subsequent to the Embody acquisition date… |
| operating_income | negative | realized | — | IPR&D recorded in 2024 acquisitions: $7.0 million which upon regulatory approval was reclassified to a definite-lived intangible and began… |